Notice of Intent: Gemini Bio-GemCell TM Plus Xeno free Reagents
ID: 24-013197Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/12ecde66295449d0b3a68a31696342b5/view
Timeline
    Description

    The National Institutes of Health (NIH) intends to award a sole-source contract to Gemini Bio for the supply of GemCell™ Plus Xeno-Free reagents, essential for the Center for Cellular Engineering's operations in Bethesda, Maryland. This procurement is critical as the Center relies on these specific reagents for manufacturing human cell and tissue-based products used in clinical trials, which are vital for patient care and treatment protocols. The unique compatibility of Gemini Bio's products with existing manufacturing processes makes them the only viable source, as switching vendors would incur significant costs and delays, potentially impacting patient outcomes. Interested parties may submit capability statements to Sheri Eiri at sheri.eiri@nih.gov by September 8, 2024, at 12:00 PM EST for consideration.

    Point(s) of Contact
    Sheri Eiri
    000000000
    sheri.eiri@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Notice of Intent: Gemini Bio-GemCell TM Plus Xeno free Reagents
    Currently viewing
    Presolicitation
    Similar Opportunities
    NOI Cytiva Sepax C-Pro Cell Processing Systems Software Upgrade
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed price contract for a software upgrade on two Cytiva Sepax C-Pro Cell Processing Systems. The objective of this procurement is to enhance the functionality of these systems, which are critical for the Department of Transfusion Medicine, thereby reducing the need for alternative devices and associated maintenance costs. This sole source acquisition is justified as Cytiva-Global Life Sciences Solutions USA LLC is the original equipment manufacturer and the only qualified provider for the proprietary software required for the upgrade. Interested parties must submit capability statements by November 14, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov for consideration.
    Notice of Intent to Sole Source Invetech GMP Korus SUS Kits
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) intends to award a fixed-price purchase order for GMP Korus SUS Kits to Invetech Inc., as part of a sole source procurement. The kits are essential for the Department of Transfusion Medicine, Center Cellular Engineering, which manufactures human cells and tissue-based products for clinical protocols in transplantation and gene therapy. Invetech Inc. is the only known source capable of providing these proprietary kits that are compatible with the Invetech Korus™ Counterflow Elutriation System, which is critical for the department's operations. Interested parties may submit capability statements to Sheri Eiri at sheri.eiri@nih.gov by November 14, 2024, at noon EST for consideration in this procurement process.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    Thermo Fisher Scientific Sorvall Legend Centrifuges Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Thermo Fisher Scientific for preventative maintenance services on thirty-one Sorvall Legend Centrifuges. The primary objective of this procurement is to ensure the continued operational integrity of critical laboratory equipment used in the manufacturing of cell-based therapies for patients enrolled in clinical trials, adhering to stringent FDA regulations. Given the importance of these centrifuges in supporting patient care and the potential risks associated with transitioning to a new vendor, the NIH emphasizes that only the original equipment manufacturer can perform necessary software updates and maintenance. Interested parties capable of providing similar services must submit a capability statement by November 17, 2024, to Sheri Eiri at sheri.eiri@nih.gov for consideration.
    Thermo Fisher Scientific Heracell Vios 160i CO2 Incubators Preventative Maintenance Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a firm-fixed price contract for preventative maintenance services for 54 Thermo Fisher Scientific Heracell Vios 160i CO2 incubators. This maintenance agreement is crucial for the Department of Transfusion Medicine, Center for Cellular Engineering Services, which manufactures cell-based therapies for clinical trials and is regulated by the FDA, necessitating that critical equipment is maintained in a controlled manner. The original equipment manufacturer, Thermo Fisher, is uniquely qualified to perform these services, including necessary software updates, to ensure compliance and avoid delays in patient treatments. Interested parties capable of providing similar services must submit a capability statement by November 16, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov.
    BD Biosciences Proprietary Instrumentation Package and Reagent Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure a proprietary instrumentation package and reagent kits from Becton, Dickinson & Company for the Department of Laboratory Medicine. This acquisition aims to secure essential supplies, including instrument rentals and quality control materials, necessary for the operation of the Hematology Flow Cytometry Service, which plays a critical role in patient care and research. The procurement is vital for maintaining the laboratory's capacity to deliver timely and accurate results, as the specified reagent kits are uniquely compatible with the existing BD Rhapsody™ single cell analysis system. Interested parties may submit capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by November 14, 2024, at 6:30 AM EST, as this is a presolicitation notice and not a request for quotations.
    BIOFIRE Defense, LLC Test Kits and Reagents
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a fixed-price contract to BioFire Defense, LLC for the provision of BIOFIRE® Reagent Kits and associated test kits. The procurement aims to secure proprietary test kits and reagents essential for the NIH Clinical Center's Department of Laboratory Medicine, which supports patient care and research by detecting pathogens in various patient specimens, including blood and respiratory samples. The BioFire test kits are critical for rapid diagnostics, allowing clinicians to initiate timely treatment for infections, and BioFire Defense, LLC is the sole source for these products due to compatibility requirements with government-owned analyzers. Interested parties capable of providing similar products may submit capability statements by November 17, 2024, at 12:00 PM EST to Sheri Eiri at sheri.eiri@nih.gov.
    65--Illumina Reagents and Consumables
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking sources for the procurement of Illumina Reagents and Consumables. This opportunity aims to identify potential suppliers capable of providing essential reagents and consumables used in genomic sequencing and related research applications. These products are critical for advancing biomedical research and supporting various health initiatives. Interested vendors should reach out to Ethan Mueller at ethan.mueller@nih.gov for further details regarding this sources sought notice.
    A--National Gene Vector Biorepository (NGVB)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is preparing to issue a Request for Proposals (RFP) for the National Gene Vector Biorepository (NGVB) program, aimed at supporting translational gene therapy research over a five-year period. The selected contractor will be tasked with archiving over 20,000 clinical specimens under Good Laboratory Practices (GLP), developing assays for clinical testing, and maintaining a user-friendly web-based catalogue for gene therapy reagents, all while ensuring compliance with FDA regulations. This initiative underscores the government's commitment to advancing gene therapy research and enhancing the services provided by the NGVB. Interested parties should note that the RFP details are expected to be released on November 22, 2024, and can contact Ethan J. Mueller at ethan.mueller@nih.gov or +1 301 496 2153 for further information.